SSG
BHVN

Summit Securities Group’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Summit Securities Group’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,300
Closed -$650K – 1510
2022
Q3 		$650K Buy
+4,300
New +$637K 0.05% 211

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Summit Securities Group's BHVN Position: Q3 2019 in Review

Summit Securities Group sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2019, closing a stake of 7,659 shares — an estimated $335K sold.

Summit Securities Group first reported a position in BHVN in Q2 2019 and held it in 1 quarter. The position peaked at $335K in Q2 2019. 184 funds tracked by Wall St. Rank hold BHVN as of Q3 2019.

  • Summit Securities Group reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2019 after selling out during the quarter.
  • Summit Securities Group sold 7,659 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2019, an estimated $335K.
  • Summit Securities Group first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 1 quarter.
  • Summit Securities Group's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $335K in Q2 2019.
  • 184 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2019.

Based on Summit Securities Group's 13F filing for Q3 2019, filed 18 Oct 2019.